EVENT

Meet us at CPhI North America – visit booth #1339

Dr Peter Scholes

Chief Scientific Officer

Peter has over 20 years’ experience in the pharmaceutical industry. In his role at Quotient Sciences he has been instrumental in identifying and implementing the innovative and flexible benefits of integrating pharmaceutical development and clinical testing in early research. Peter has served as a committee member for the U.K. Controlled Release Society and APS Biopharmaceutics focus group and in 2013 set up a GastroPlus™ user group with industry colleagues as a discussion forum for PBPK modelling and simulation science. In 2010, Peter was named one of PharmaVOICE’s 100 most inspiring people in the life-sciences industry. He was appointed as an Honorary Professor in Pharmaceutical Sciences at Nottingham University in August 2015.

Dr Stuart Harris

Executive Medical Director

Dr Stuart Harris has 22 years’ experience of Phase I research and is formerly the co-founder of SeaView Research. He has been a Clinical Investigator specializing in Phase I and early Phase II trials since 1988. Dr Harris has previously held roles as Vice Chairman and Secretary of Pollo Tropical Inc., Medical Director at South Florida Bioavailability Clinic, and Medical Director at SeaView Research. As a Board Certified Internist he received his MD and PhD (Physiology/Pharmacology) degrees at Duke University.

Dr Stuart Mair

Medical Director

Stuart has over 15 years’ experience of delivering exploratory clinical studies in the CRO Industry, he has delivered over 100 First in Human studies and is an expert in the design and implementation of exploratory clinical trials from First-in-Human to Proof-of-Concept in patient groups with PD biomarkers. He has advised clients on multiple study types from simple PK, BE and characterisation studies to complex flexible designs with multiple portions delivered under a single protocol.

Dr Nutan Gangrade

Managing Director - Philadelphia

Commercial manufacturing

Clinical trial manufacturing

Nutan brings has over 25 years' experience within the pharmaceutical industry. Prior to his current role, Nutan served as Senior Director of Formulation Development at QS Pharma and is a founding team member. He has previously held positions at Bristol-Myers Squibb (DuPont Pharmaceuticals Company) and Wyeth-Ayerst Research (American Cyanamid Company). In these positions, he was the CMC lead for several products in various phases of development. Nutan graduated with a Ph.D. in Pharmaceutics from the University of Georgia.

Nikki Whitfield

Vice-President, CDMO Services

Formulation development

Clinical trial manufacturing

Nikki possesses 23 years’ experience in the pharmaceutical industry and has previously held technical leadership positions in Quadrant Healthcare, Quadrant Drug Delivery and Elan where she was responsible for the development, transfer and scale up of both early phase and late phase spray-dried inhaled and topical products intended for both European and U.S. markets. In her previous position as a Project Director at Vectura, she led the early phase product development for two inhaled, orphan indication products and the late stage development for a novel sterile topical product. Nikki’s responsibilities at Quotient Sciences involve building the global formulation and manufacturing services business.

Dr Vanessa Zann

Senior Research Fellow

Translational Pharmaceutics

Clinical pharmacology

Vanessa has over 17 years industry experience providing biopharmaceutics support to discovery, development and clinical programs. Vanessa has previous experience at AstraZeneca as a permeability expert working in the Pharmaceutical Development dept. where she lead the global Caco-2 facility for development, liaising with discovery scientists to ensure selection of NCE with appropriate biopharmaceutical properties, introduced the IV microtracer technique and also provided biopharmaceutical support to both Discovery and Development programs. Vanessa joined Quotient Sciences in 2012 and has lead the implementation of Modelling and Simulation and been heavily involved in the Pharmaceutical Sciences in vitro characterisation strategy, as well as designing clinical studies and providing scientific support through clinical study delivery.

Dr Prasad Challapalli

Director, Formulation Development

Commercial manufacturing

Clinical trial manufacturing

Prasad has over 25 years’ professional experience, with 15 years’ in the CMO industry. Prasad develops and implements suitable workflows to achieve operational excellence in the manufacture of products, and mentors and manages formulation scientists and manufacturing teams. Prior to his current role at Quotient Sciences, Prasad worked at QS Pharma as Director of Formulation Development, and at Patheon, as Manager of Business Development Services and Senior Scientific Leader in the Formulation Process Development Group.

Dr Kieran Crowley

Senior Scientific Director

Translational Pharmaceutics

Clinical pharmacology

Kieran has over 15 years’ experience leading Pre-formulation and Formulation Development teams in both innovator and contract manufacturing organisations. His expertise is in selecting and optimising drug delivery systems based on the physicochemical and biopharmaceutics properties of the active ingredient. Oral delivery of poorly soluble compounds is a particular field of experience and interest, in which he has successfully advanced products using hot melt extrusion, nanomilling and lyophilisation. Kieran’s responsibilities at Quotient Sciences include the design and implementation of integrated pharmaceutical and clinical development programs, utilizing Quotient’s ability to manufacture drug products in real-time in response to arising human data.

Dr Helen Walker

Senior Research Fellow

Translational Pharmaceutics

Clinical pharmacology

Helen has over 20 years’ experience working in drug research and development. The majority of Helen’s experience comes from working within AstraZeneca and her areas of expertise are Clinical Pharmacology and Drug Metabolism and Pharmacokinetics (DMPK). Other specialist areas include the application of modelling and simulation and the use of biomarkers within clinical development programs. She has supported projects in both early and late stage clinical development. Helen’s responsibilities at Quotient Sciences include providing scientific input into programs of work to ensure innovative design which maximises data for the client and delivers the study objectives.

Dr Alyson Connor

Executive Director, Exploratory Clinical Pharmacology

Translational Pharmaceutics

Clinical pharmacology

Alyson has 20 years’ experience in the design and conduct of clinical programs, with particular emphasis on the use of adaptive and umbrella protocols to streamline the transition from First-in-Human to Proof-of-Concept. After fulfilling roles in the Project Management, Operational and Scientific departments, Alyson was appointed to lead the global Exploratory Clinical Pharmacology portfolio in 2013. Alyson’s responsibilities include oversight of the design and implementation of clinical development programs. Alyson is also an acknowledged expert in the visualization of dosage forms via gamma scintigraphy, and regularly publishes on the subject.

John McDermott

Executive Director, Drug Product Optimisation

Translational Pharmaceutics

Formulation development

John has over 15 years industry experience in roles in pharmaceutical sciences with Rhone Poulenc Rorer, Covance and Quotient Sciences, which he joined in 2001. After fulfilling roles in the development and validation of radiolabelling methods for oral and inhaled dosage forms, and leading Quotient’s analytical group, John was appointed to his current position and now has overall responsibility for Drug Product Optimization.

Iain Shaw

Director, 14-C Enabled Drug Development

Translational Pharmaceutics

Clinical pharmacology

Iain has over 20 years drug development experience having previously held early development program management, clinical development and analytical posts in the pharmaceutical industry and contract research organisations. Prior to his current role he was a Program Manager in early drug development at Covance. He has previously held various analytical, project management and clinical development posts in the pharmaceutical, agrochemical and contract research industries. In total he has 30 years industrial experience. Iain’s responsibilities at Quotient Sciences include all 14C clinical activities since April 2009.

Ask us a question

With two simple steps we can help you with your drug development challenges.

Simply select the most relevant scientist(s) and submit your question(s).
You can select more than one expert. We will respond within 48 hours.

  • Dr Nutan Gangrade

    Managing Director - Philadelphia

    Commercial manufacturing

    Clinical trial manufacturing

  • Nikki Whitfield

    Vice-President, CDMO Services

    Formulation development

    Clinical trial manufacturing

  • Dr Vanessa Zann

    Senior Research Fellow

    Translational Pharmaceutics

    Clinical pharmacology

  • Dr Prasad Challapalli

    Director, Formulation Development

    Commercial manufacturing

    Clinical trial manufacturing

  • Dr Kieran Crowley

    Senior Scientific Director

    Translational Pharmaceutics

    Clinical pharmacology

  • Dr Helen Walker

    Senior Research Fellow

    Translational Pharmaceutics

    Clinical pharmacology

  • Dr Alyson Connor

    Executive Director, Exploratory Clinical Pharmacology

    Translational Pharmaceutics

    Clinical pharmacology

  • John McDermott

    Executive Director, Drug Product Optimisation

    Translational Pharmaceutics

    Formulation development

  • Iain Shaw

    Director, 14-C Enabled Drug Development

    Translational Pharmaceutics

    Clinical pharmacology

Ask your questions here

Your questions will be sent to the following experts:

Dr Peter Scholes

Chief Scientific Officer

Dr Stuart Harris

Executive Medical Director

Dr Stuart Mair

Medical Director

Dr Nutan Gangrade

Managing Director - Philadelphia

Commercial manufacturing

Clinical trial manufacturing

Nikki Whitfield

Vice-President, CDMO Services

Formulation development

Clinical trial manufacturing

Dr Vanessa Zann

Senior Research Fellow

Translational Pharmaceutics

Clinical pharmacology

Dr Prasad Challapalli

Director, Formulation Development

Commercial manufacturing

Clinical trial manufacturing

Dr Kieran Crowley

Senior Scientific Director

Translational Pharmaceutics

Clinical pharmacology

Dr Helen Walker

Senior Research Fellow

Translational Pharmaceutics

Clinical pharmacology

Dr Alyson Connor

Executive Director, Exploratory Clinical Pharmacology

Translational Pharmaceutics

Clinical pharmacology

John McDermott

Executive Director, Drug Product Optimisation

Translational Pharmaceutics

Formulation development

Iain Shaw

Director, 14-C Enabled Drug Development

Translational Pharmaceutics

Clinical pharmacology

Ask us a question